
	Where results make sense

Topic: Gilead Sciences

Related Topics

Genentech

Biogen Idec

Amgen

Donald Rumsfeld

NEC Corporation

RAND Corporation

Santa Monica

Biotechnology

Indianapolis 500

Nation of Islam

Miriam Colon

Billboard Hot 100

USA PATRIOT Act

Miguel Cotto

Ricky Martin

In the News (Sun 3 Jun 12)

EXECUTIVE POWER

Iran

ANALYSIS

Pakistan

Family compact

	Gilead -- Careers
		Gilead people are accomplished experts driven to make a difference in the lives of patients suffering from life-threatening diseases worldwide.
		With approximately 1,800 employees around the globe, Gilead engages approximately 60 percent of its staff in research and development functions, 23 percent in sales and marketing and 17 percent in general and administrative positions.
		Gilead Sciences is proud to be an equal opportunity employer and extends employment to men and women from culturally diverse backgrounds.
	www.gilead.com /wt/sec/careers (171 words)

	Gilead Sciences - Wikipedia, the free encyclopedia
		Gilead Sciences NASDAQ: GILD is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases, principally HIV, hepatitis B and influenza.
		Gilead (a place mentioned in the Bible) was famed for its small trees that produced a resin used in medicine.
		Later that year Hepsera (adefovir) was approved for the treatment of chronic hepatitis B, and Emtriva (emtricitabine) for the treatment of HIV.
	en.wikipedia.org /wiki/Gilead_Sciences (565 words)

	Gilead Sciences (Site not responding. Last check: 2007-10-08)
		Gilead Sciences, Inc., headquartered in Foster City, California, is an independent biopharmaceutical company that seeks to provide accelerated treatment solutions for patients and the people who care for them.
		Gilead focuses its extensive research and development efforts on two key development areas - infectious diseases and oncology - at three locations in the United States and nine throughout Europe and Australia.
		Gilead's strength in the research, development and commercialization of antiviral therapies led to U.S. Food and Drug Administration (FDA) approval and market launch in 1996 of our first commercial product, VISTIDE® (cidofovir injection), for the treatment of cytomegalovirus retinitis in patients with AIDS.
	www.acor.org /drugs/pipeline/companies/Gilead+Sciences.tmp (518 words)

	BW 50: Gilead Sciences Profile
		Gilead Sciences has built an emerging biotech brand with its HIV treatments.
		For an encore Gilead is teaming up with Bristol-Myers Squibb Co. (BMY) to combine Gilead's Truvada with Bristol's Sustiva Profile: the first time patients will be able to take one daily pill, not six, for their complete regimen.
		Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for serious diseases.
	www.businessweek.com /bw50/2005/company/GILD.htm (394 words)

	Gilead Sciences News
		Whitehouse Station, N.J.-based Merck and Foster City, Calif.-based Gilead Sciences on Wednesday at the 13th Conference on Retroviruses and Opportunistic Infections in Denver reported "surprisingly strong"...
		Gilead Sciences Inc.'s said fourth-quarter profit more than doubled as sales climbed for the company's Truvada medicine, which combines two HIV drugs into a single, once-a-day pill.
		Gilead Sciences Launches Stop Hep B Campaign; Initiative Aims to...
	www.topix.net /com/gild (673 words)

	GILEAD SCIENCES INC Unscheduled Material Events (8-K) EXHIBIT 99.1
		Foster City, CA and Redwood City, CA, September 30, 2004 - Gilead Sciences (Nasdaq: GILD) and Genelabs Technologies, Inc. (Nasdaq: GNLB) today announced that the companies have signed an agreement to collaborate in the research, development and commercialization of novel compounds for the treatment of infection caused by the hepatitis C virus (HCV).
		"Gilead has proven to be a potent force in the development and commercialization of antiviral products and is an ideal partner for Genelabs' HCV program," said James A. Smith, President and Chief Executive Officer of Genelabs.
		These and other risks are described in detail in the Gilead Annual Report on Form 10-K and the Genelabs Annual Report on Form 10-K, each for the year ended December 31, 2003 and in each company's Quarterly Reports on Form 10-Q, all of which are on file with the U.S. Securities and Exchange Commission.
	sec.edgar-online.com /2004/10/04/0001104659-04-029521/section6.asp (772 words)

	Press release : GILEAD SCIENCES INC CompanynewsGroup
		Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its corporate presentation will be webcast at two upcoming investor conferences: the Sanford Bernstein 21st Annual Strategic Decisions Conference, and the 9th Annual Friedman, Billings, Ramsey Growth Investor Conference, both taking place in New York, New York.
		John Martin, Ph.D., Gilead's President and Chief Executive Officer, will provide an overview of the company and an update on key business milestones first at the Sanford Bernstein conference on Wednesday, June 1st at 4:00 p.m.
		Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.
	www.companynewsgroup.com /communique.asp?co_id=102261 (373 words)

	Gilead Sciences (Site not responding. Last check: 2007-10-08)
		Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide.
		The Company markets Viread (tenofovir disoproxil fumarate) for HIV, the virus that causes AIDS; AmBisome (amphotericin B) liposome for injection), for life-threatening fungal infections ; DaunoXome (daunorubicin citrate liposome injection), a drug approved for the treatment of AIDS-related Kaposi's Sarcoma ; and Vistide (cidofovir injection) for the treatment of AIDS-related CMV retinitis.
		Gilead is also developing products to treat diseases caused by hepatitis B virus and gram-positive bacterial infections.
	www.acor.org /drugs/pipeline/companies/profiles/1394.data.orig (232 words)

	Netherlands Corporate News - Gilead Sciences: promoties in het management (Site not responding. Last check: 2007-10-08)
		As Senior Vice President and General Counsel, he is responsible for legal affairs as well as Gilead's government affairs activities, reporting to John C. Martin, PhD, Gilead's President and Chief Executive Officer.
		He is Chairman of the Board of BayBio, a San Francisco Bay Area life sciences industry organization, a member of the board of the AIDS Healthcare Foundation, member of the board and treasurer of the Biotechnology Industry Organization's General Counsel Committee, and a member of the advisory board of BIO Ventures for Global Health.
		"In particular, with the growth of Gilead and our marketed products, Taiyin and her team have effectively managed the rapid scale-up of production of active pharmaceutical ingredients for our antiretrovirals for HIV." About Gilead Sciences Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.
	www.netherlandscorporatenews.com /archive/en/2005/07/29/v003.htm (547 words)

	Gilead Sciences (Site not responding. Last check: 2007-10-08)
		From our inception, the people of Gilead across the United States, Europe, Australia and Canada have shared a vision of advancing therapeutics for life-threatening diseases worldwide.
		Gilead today has seven marketed products and a clinical, preclinical and research pipeline focused on developing anti-infectives.
		The evolution of Gilead and our track record of success is testament to what the company has achieved through disciplined science, visionary thinking and diversified planning.
	www.infectiousdiseasenews.com /advert/gilead-d.asp (270 words)

	Press release : GILEAD SCIENCES INC CompanynewsGroup
		GILEAD SCIENCES INC : Un membro del Consiglio d’amministrazione di Gilead Sciences stabilisce un piano di trading di azioni secondo il regolamento 10b5-1
		FOSTER CITY, Calif.--(BUSINESS WIRE)—17 Agosto 2004--Gilead Sciences, Inc. (Nasdaq:GILD) ha annunciato oggi che James M. Denny, presidente non esecutivo del Consiglio d’amministrazione di Gilead, ha stabilito un piano di trading di azioni secondo il regolamento 10b5-1del Securities Exchange Act del 1934.
		Rule 10b5-1 allows insiders to adopt written plans for trading securities in a non-discretionary, pre-scheduled manner in order to avoid concerns about initiating stock transactions when the insider may be aware of non-public information.
	www.companynewsgroup.com /communique.asp?co_id=91294 (305 words)

	Gilead Sciences Stock Report (GILD) \| Quote & News
		Gilead Sciences Launches Stop Hep B Campaign; Initiative Aims to Combat Chronic Hepatitis B by Educating and Empowering At-Risk Communities (BWI)
		Gilead Sciences develops and produces therapeutics for life-threatening infectious diseases.
		Gilead currently has three products--Viread, Emtriva, and combination pill Truvada--in its HIV franchise, and Hepsera for hepatitis B. The company is focusing on expanding its HIV franchise and continuing research in both hepatitis B and C. Read full analyst report
	quote.morningstar.com /quote.html?ticker=gild (242 words)

	Gilead Sciences "outperform" \| newratings.com (Site not responding. Last check: 2007-10-08)
		Gilead Sciences quote - chart - all headlines - analyst actions - add to watchlist
		In a research note published this morning, the analyst mentions that the company has sent a notice to Roche for the termination of their marketing partnership for Tamiflu.
		The importance of Tamiflu has increased over the recent years and Gilead Sciences intends to reclaim Tamiflu's total marketing and manufacturing rights, the analyst says.
	www.newratings.com /analyst_news/article_889564.html (237 words)

	Gilead Sciences (Site not responding. Last check: 2007-10-08)
		Headquartered in Foster City, CA, Gilead has operations in the United States, Europe and Australia.
		Perform ongoing evaluation of Gilead in-house versus CRO biometrics activities.
		PhD in biostatistics with 12 years of experience in clinical trials is required.
	www.stat.ufl.edu /vlib/jobs/gilead.html (334 words)

	Avian Flu - What we need to know: Vaccines (Site not responding. Last check: 2007-10-08)
		Based upon the lab and mice testing, Gemini Science is now initiating pre-clinical studies required for the commencement of human clinical testing of the anti-M2 antibody, said Shinichiro Kato, Ph.D., Gemini's Chief Scientific Officer.
		Gilead Sciences, which invented the drug, said yesterday that it wanted to take back the rights to the drug from Roche, which makes and sells it.
		Gilead said Roche had not done enough to manufacture and promote the drug, thereby violating the 1996 contract between the companies.
	avianflu.typepad.com /avianflu/vaccines/index.html (7601 words)

	Gilead Sciences Press Releases
		FOSTER CITY, Calif.-- --Feb. 6, 2006--Gilead Sciences, Inc. today announced the establishment of a stock trading plan under Rule 10b5-1 of the Securities Exchange Act of 1934 on February 2, 2006 by Paul Berg,...
		Gilead Launches an Educational Website on Advances in Combination Therapy For HIV
		Gilead and Roche End Tamiflu(R) Dispute; Expanded Collaboration...
	www.topix.net /com/gild/pr (607 words)

	Gilead Sciences, Inc. information and related industry information from Hoover's
		Gilead Sciences has biotech balms for infectious diseases, including the flu, HIV, and infections related to AIDS.
		There are 16 competitors for Gilead Sciences; see more.
		Get more info on Gilead Sciences with a DandB Report.
	www.hoovers.com /gilead-sciences/--ID__15080--/free-co-factsheet.xhtml (424 words)

	Gilead Sciences (Site not responding. Last check: 2007-10-08)
		Primary responsibility would be to manage a small team of statistical programmers ensuring programming and corresponding documentation is completed in a manner that is consistent with departmental procedures.
		BS degree in Biostatistics/Computer Science or equivalent + at least 8 years relevant industry experience or MS degree + at least 6 years relevant industry experience or PhD + at least 2 years relevant industry experience in statistical analysis of biomedical data using SAS software.
		Must have a thorough understanding of clinical trials design and reporting process, as well as regulatory reporting requirements, including electronic data submissions.
	www.basas.com /pages/j_gilead.htm (108 words)

	Gilead Sciences Announces
		Foster City, CA, December 3, 1999 - Gilead
		Gilead will focus its development efforts on its
		Gilead has decided to halt new enrollment in its
	www.hiv.ch /rubriken/therapie/medikamente/gilead991203.htm (282 words)

	Gilead Sciences (GILD) Stock Research - Stock Quotes, Charts, News and Analysis
		Gilead Sciences (GILD) Stock Research - Stock Quotes, Charts, News and Analysis
		Make Gilead Sciences your first of 30 commission free trades.
		The principal activities of the Company is to discover, develop and commercialize therapeutics to treat patients worldwide suffering from life-threatening diseases.
	www.investorguide.com /stock.cgi?stock=GILD (293 words)

	Business Weekly - Profile - Gilead Sciences Inc
		Gilead, the international biopharma company, is opening a new UK headquarters at Granta Park’s Flowers Building at the end of June.
		Gilead starts trials of new ovarian cancer treatment
		Gilead Sciences Inc, the NASDAQ firm which has R & D facilities in Cambridge, has started the first Phase II clinical trial of NX 211 - an investigational compound to treat patients with relapsed ovarian cancer or other solid tumours.
	www.businessweekly.co.uk /directory/profile.asp?company_id=489 (164 words)

	MSN Money - GILD - Stock quote, Mutual fund quote, ETF quote, Index quote, Options quote (Site not responding. Last check: 2007-10-08)
		Gilead Sciences to Present at Two Upcoming Inv...
		Gilead Sciences to Present at the Citigroup 20...
		The Dow drops 63 points as 10-year Treasurys hit their highest levels since June 2004.
	moneycentral.msn.com /msn/stock_quote?Symbol=GILD (106 words)

	Truvada
		Gilead is preparing an update to this Web site to reflect changes to the Truvada Prescribing Information that were effective in May 2005.
		For a copy of the updated Prescribing Information, click here.
		Should you have any questions concerning the revised Prescribing Information, please contact the Gilead Medical Information Department at 1-800-GILEAD-5 (1-800-445-3235).
	www.truvada.com (391 words)

	FindLaw Business Contracts : By Alpha : G : Gilead Sciences Inc.
		Asset Purchase Agreement - Gilead Sciences Inc. and OSI Pharmaceuticals Inc. (Nov 26, 2001)
		License Agreement - Gilead Sciences Inc., the Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic, and Rega Institute for Medical Research (Dec 27, 2000)
		License and Supply Agreement - Gilead Sciences Inc. and Pharmacia & Upjohn SA (Aug 7, 1996)
	contracts.corporate.findlaw.com /alpha/g/576.html (504 words)

	Gilead Sciences (Site not responding. Last check: 2007-10-08)
		03/19/99 Gilead Presents Clinical Data Demonstrating That 60 mg PREVEON is as Effective as 120 mg for HIV Infection With Improved Safety Profile
		03/17/99 Gilead Begins Multinational Phase III Trial of Oral Hepatitis B Drug, Adefovir Dipivoxil; Phase II Data Show Rapid Reduction of Virus Levels by 99.99% and 20% Seroconversion
		03/03/99 Gilead Sciences Announces Preliminary Results From Studies of PREVEON 60 Mg for HIV Infection
	www.businesswire.com /cnn/gild.shtml (380 words)

	Right-Web \| Individual Profile \| George P. Shultz
		Stanford University Center for Advanced Study in the Behavioral Sciences: Fellow (1968-1969) (1)
		Gilead Sciences: Member of Board of Directors (1996-current) (1, 2)
		(3) Gilead Sciences Board of Directors: George P. Shultz
	rightweb.irc-online.org /ind/shultz/shultz.php (336 words)

	Gilead Sciences Inc Patents
		This is a recent list of patent applications and is not meant to be a comprehensive history.
		Also note that there may be alternative spellings for Gilead Sciences Inc with additional patents.
		Browse the Agent directory for other possible listings.
	www.freshpatents.com /Gilead-Sciences-Inc-cndirg.php (107 words)

	Viread (tenofovir disoproxil fumarate) - Viread.com (Site not responding. Last check: 2007-10-08)
		Gilead is preparing an update to this Web site to reflect changes to the Viread Prescribing Information that were effective in May 2005.
		To learn more about Viread, click on one of the following:
		Click here to read the full Viread.com site disclaimer.
	www.viread.com (142 words)

Try your search on: Qwika (all wikis)